Savella, also known by its generic name, milnacipran, is a medication used to treat fibromyalgia. Its price can vary significantly depending on factors such as dosage, quantity, and the pharmacy where it is purchased.
How much does Savella cost without insurance?
The retail price for a 30-day supply of Savella, typically 100 mg twice daily, can range from approximately $300 to over $400. For example, a 60-count bottle of 50 mg tablets might cost around $200, while a 120-count bottle could be upwards of $400. These prices are before any insurance coverage or discount programs are applied [1].
Can I get a discount on Savella?
Several options exist to potentially reduce the cost of Savella. Pharmaceutical company coupons or savings cards may be available, often offering significant discounts for eligible patients. Prescription discount cards and online pharmacies can also provide lower prices compared to traditional brick-and-mortar pharmacies [1].
What is the price of generic milnacipran?
Milnacipran is the generic name for Savella. Generic versions of the drug are typically less expensive than their brand-name counterparts. However, availability of generic milnacipran may vary by region and pharmacy. When available, the cost of generic milnacipran can be substantially lower than brand-name Savella, potentially bringing the monthly cost down considerably [2].
How does insurance affect Savella's price?
Insurance coverage plays a crucial role in the out-of-pocket cost of Savella. Most insurance plans will cover Savella, but the exact cost to the patient will depend on their specific plan's formulary, deductible, copay, and coinsurance. Patients are advised to check with their insurance provider to understand their coverage for Savella or its generic equivalent [2].
When does the patent for Savella expire?
Information regarding the specific patent expiry dates for Savella is typically managed by specialized services. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be a resource for determining when exclusivity for the drug may end, potentially opening the door for generic competition [3].